Starczewski Andrzej, Brodowska Agnieszka, Brodowski Jacek
Department of Reproduction and Gynecology, Pomeranian Medical University of Szczecin, Poland.
Pol Merkur Lekarski. 2009 Mar;26(153):231-3.
Pelvic endometriosis in women is a very common disease. The incidence of this condition in Poland in reproductive age women is about 7-15%, and as much as 50% of cases is diagnosed in patients with co-existing infertility and/or pain and adhesion of a true pelvis. The choice of a therapeutic method depends on the patient's age, stage of the disease, desire for pregnancy, the presence of adhesion, focus localization and a reaction to previous treatment. Currently, the most popular is surgical treatment sometimes followed by pharmacotherapy. Pharmacological treatment includes hormone therapy and symptomatic treatment, also the use of painkillers. Hormonal agents are administered to suppress ovarian activity and cause atrophy of ectopic foci of endometrium. At present, post-surgical pharmacotherapy for endometriosis uses mainly such hormones as: the Combined Oral Contraceptive Pill (COCP), progestagens, danazol, GnRh (gonadotropin-releasing hormone) analogues, aromatase inhibitors and other less common drugs. Also other therapeutic procedures are recommended in endometriosis treatment, procedures which support and in certain clinical situations even replace classical pharmacological methods. Some of them are immunotherapy and a diet rich in isoflavones, organic compounds which modulate estrogen receptor activity. Numerous clinical trials proved that preoperative pharmacotherapy does not improve treatment results and is not applicable to endometriomas in women. On the other hand, postoperative pharmacotherapy still ignites controversy. As maintained by the most recent literature, in the case of mild endometriosis (clinical Stage I and II according to the American Society for Reproductive Medicine) endometrial ablation has better effects than observation only, however postoperative pharmacotherapy does not improve the results of treatment. In more severe cases (clinical Stage III and IV), the best results are achieved by the combined treatment. Nevertheless, no randomized research has been carried out on a wide scale in this group of patients.
女性盆腔子宫内膜异位症是一种非常常见的疾病。在波兰,育龄女性中这种疾病的发病率约为7%-15%,高达50%的病例是在同时存在不孕和/或真性骨盆疼痛及粘连的患者中被诊断出来的。治疗方法的选择取决于患者的年龄、疾病阶段、怀孕意愿、粘连情况、病灶位置以及对先前治疗的反应。目前,最常用的是手术治疗,有时术后还会进行药物治疗。药物治疗包括激素治疗和对症治疗,也会使用止痛药。使用激素类药物来抑制卵巢活动并使子宫内膜异位病灶萎缩。目前,子宫内膜异位症术后药物治疗主要使用以下几种激素:复方口服避孕药(COCP)、孕激素、达那唑、GnRh(促性腺激素释放激素)类似物、芳香化酶抑制剂以及其他不太常用的药物。子宫内膜异位症治疗中还推荐了其他一些治疗方法,这些方法在某些临床情况下可以辅助甚至替代传统的药物治疗方法。其中一些方法是免疫疗法和富含异黄酮的饮食,异黄酮是一种可调节雌激素受体活性的有机化合物。大量临床试验证明,术前药物治疗并不能改善治疗效果,也不适用于女性卵巢子宫内膜异位囊肿。另一方面,术后药物治疗仍然存在争议。根据最新文献,对于轻度子宫内膜异位症(根据美国生殖医学学会的临床I期和II期),子宫内膜消融术比单纯观察效果更好,然而术后药物治疗并不能改善治疗结果。在更严重的病例(临床III期和IV期)中,联合治疗能取得最佳效果。然而,尚未在这类患者中进行大规模的随机研究。